Healthcare Resource Utilization of Second-Generation Long-Acting Injectable Antipsychotics in Schizophrenia: Risperidone versus Paliperidone Palmitate.
CONCLUSIONS: These findings highlight the value of once-monthly paliperidone palmitate in the treatment of patients with schizophrenia.
PMID: 27479694 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Databases & Libraries | Emergency Medicine | Health | Healthcare Costs | Insurance | Invega | Invega Sustenna | Medicaid | Medicare | Research | Risperdal Consta | Schizophrenia | Study